Logo image of VOR

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD

0.65  0 (0%)

After market: 0.65 0 (0%)

Fundamental Rating

2

Taking everything into account, VOR scores 2 out of 10 in our fundamental rating. VOR was compared to 568 industry peers in the Biotechnology industry. VOR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VOR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VOR has reported negative net income.
In the past year VOR has reported a negative cash flow from operations.
VOR had negative earnings in each of the past 5 years.
In the past 5 years VOR always reported negative operating cash flow.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -81.82%, VOR is doing worse than 69.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of -120.95%, VOR is in line with its industry, outperforming 40.49% of the companies in the same industry.
Industry RankSector Rank
ROA -81.82%
ROE -120.95%
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

VOR has more shares outstanding than it did 1 year ago.
VOR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.57, we must say that VOR is in the distress zone and has some risk of bankruptcy.
VOR has a worse Altman-Z score (-5.57) than 61.44% of its industry peers.
VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.57
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

VOR has a Current Ratio of 5.19. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
VOR's Current ratio of 5.19 is in line compared to the rest of the industry. VOR outperforms 56.16% of its industry peers.
A Quick Ratio of 5.19 indicates that VOR has no problem at all paying its short term obligations.
VOR has a Quick ratio (5.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.19
Quick Ratio 5.19
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.41% over the past year.
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.78% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.48%
EPS Next 2Y22.31%
EPS Next 3Y13.68%
EPS Next 5Y18.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as VOR's earnings are expected to grow with 13.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.31%
EPS Next 3Y13.68%

More info and screens

0

5. Dividend

5.1 Amount

VOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOR BIOPHARMA INC

NASDAQ:VOR (4/17/2025, 8:00:02 PM)

After market: 0.65 0 (0%)

0.65

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners49.54%
Inst Owner Change-0.03%
Ins Owners0.74%
Ins Owner Change95.96%
Market Cap81.15M
Analysts86.67
Price Target10.35 (1492.31%)
Short Float %1.71%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-25.51%
Min EPS beat(2)-52.48%
Max EPS beat(2)1.46%
EPS beat(4)2
Avg EPS beat(4)-16.47%
Min EPS beat(4)-52.48%
Max EPS beat(4)2.83%
EPS beat(8)3
Avg EPS beat(8)-7.54%
EPS beat(12)5
Avg EPS beat(12)-4.45%
EPS beat(16)8
Avg EPS beat(16)-1.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.94%
PT rev (3m)-24.4%
EPS NQ rev (1m)5.64%
EPS NQ rev (3m)18.66%
EPS NY rev (1m)17.57%
EPS NY rev (3m)24.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.82%
ROE -120.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.19
Quick Ratio 5.19
Altman-Z -5.57
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.82%
EPS Next Y46.48%
EPS Next 2Y22.31%
EPS Next 3Y13.68%
EPS Next 5Y18.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.63%
OCF growth 3YN/A
OCF growth 5YN/A